These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37812893)

  • 1. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis.
    Xiang D; Yang J; Liu L; Yu H; Gong X; Liu D
    Biomed Pharmacother; 2023 Dec; 168():115606. PubMed ID: 37812893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
    Radun R; Trauner M
    Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
    Sun L; Cai J; Gonzalez FJ
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
    Zhou W; Anakk S
    Mol Cell Endocrinol; 2022 Jun; 549():111616. PubMed ID: 35304191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling.
    Taylor RE; Bhattacharya A; Guo GL
    Drug Metab Dispos; 2022 Apr; 50(4):456-467. PubMed ID: 34759011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FXR in Cholestasis.
    Keitel V; Dröge C; Häussinger D
    Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
    Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
    Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of farnesoid X receptor and its role in bile acid metabolism.
    Chiang JYL; Ferrell JM
    Mol Cell Endocrinol; 2022 May; 548():111618. PubMed ID: 35283218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism.
    Kumari A; Pal Pathak D; Asthana S
    Int J Biol Sci; 2020; 16(13):2308-2322. PubMed ID: 32760200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FXR: structures, biology, and drug development for NASH and fibrosis diseases.
    Tian SY; Chen SM; Pan CX; Li Y
    Acta Pharmacol Sin; 2022 May; 43(5):1120-1132. PubMed ID: 35217809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile acids as regulators of hepatic lipid and glucose metabolism.
    Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
    Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile Acids and FXR: Novel Targets for Liver Diseases.
    Stofan M; Guo GL
    Front Med (Lausanne); 2020; 7():544. PubMed ID: 33015098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
    Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
    Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile Acids and Farnesoid X Receptor in Renal Pathophysiology.
    Yang J; Pontoglio M; Terzi F
    Nephron; 2024; 148(9):618-630. PubMed ID: 38412845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease.
    van Zutphen T; Bertolini A; de Vries HD; Bloks VW; de Boer JF; Jonker JW; Kuipers F
    Handb Exp Pharmacol; 2019; 256():207-234. PubMed ID: 31236687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
    Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
    Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity.
    Rausch M; Samodelov SL; Visentin M; Kullak-Ublick GA
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.